...
首页> 外文期刊>Cell death & disease. >Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma
【24h】

Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma

机译:降低细胞分裂素1的蛋白调节剂作为肝细胞癌的前瞻性治疗

获取原文
           

摘要

Proteins that bind to microtubule are important for cell cycle, and some of these proteins show oncogenic characteristics with mechanisms not fully understood. Herein we demonstrate overexpression of protein regulator of cytokinesis 1 (PRC1), a microtubule-associated regulator of mitosis, in human hepatocellular carcinoma (HCC). Moreover, upregulated PRC1 is associated with lower survival rates of HCC patients. Mechanistically, reducing PRC1 blocks mitotic exit of HCC cells at telophase in a spindle assembly checkpoint independent manner, and acts synergistically with microtubule-associated agents (MTAs) to suppress p53-wt or p53-null HCC cells in a p53- or p14ARF-dependent manner; while overexpressing PRC1 increases the resistance of HCC to taxol. A combined treatment of taxol/shPRC1 results in 90% suppression of tumor growth in subcutaneous HCC xenograft models. In orthotopic xenograft mice, reducing PRC1 significantly alleviates HCC development and hepatic injury. Together, our results suggest a dual-mitotic suppression approach against HCC by combining MTAs with cytokinesis inhibition, which blocks mitosis at both metaphase and telophase.
机译:结合微管的蛋白质对于细胞周期很重要,其中一些蛋白质显示出致癌特性,其机理尚不完全清楚。在本文中,我们证明了人类肝细胞癌(HCC)中胞质分裂1(PRC1)的蛋白表达,一种微管相关的有丝分裂调控因子。此外,PRC1上调与肝癌患者较低的生存率相关。机械上,减少PRC1以纺锤体装配检查点独立的方式阻断HCC细胞在末期的有丝分裂退出,并与微管相关剂(MTA)协同作用,以抑制p53或p14ARF依赖性的p53-wt或p53-null HCC细胞方式;而过表达PRC1则会增加HCC对紫杉醇的耐药性。紫杉醇/ shPRC1的联合治疗可在皮下HCC异种移植模型中抑制90%的肿瘤生长。在原位异种移植小鼠中,降低PRC1可以显着减轻HCC的发展和肝损伤。总之,我们的结果表明,通过将MTA与胞质分裂抑制作用相结合,可对HCC进行双重有丝分裂抑制,从而在中期和末期均能阻止有丝分裂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号